Healthcare >> CEO Interviews >> August 12, 2016

Interview with the CFO: Ignyta, Inc. (NASDAQ:RXDX)

Chacko, Jacob
Jacob Chacko, M.D. is Chief Financial Officer at Ignyta, Inc. Dr. Chacko brings to the company a broad range of experience with financing, managing and advising companies in the life sciences field. Dr. Chacko joined Ignyta, Inc. in May 2014 from TPG Capital, a global private investment firm with approximately $60 billion of assets under management, where he served as a Vice President focused primarily on health care and digital media since August 2008. At TPG Capital, Dr. Chacko helped lead teams that successfully completed acquisitions having an aggregate value of over $10 billion. He served on the boards of directors of RentPath and EnvisionRx, was an adviser to the audit committee of Par Pharmaceutical and was a board observer to IMS Health and Quintiles Transnational. Dr. Chacko currently serves on the board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford and on the Western Regional Selection Committee for the Marshall Scholarship. Prior to TPG Capital, Dr. Chacko concurrently received his M.D. with AOA honors from UCLA and his MBA with distinction from Harvard Business School, and was president of his class at both institutions. Prior to this, Dr. Chacko was a Consultant serving health care clients at the management consulting firm McKinsey & Company. Dr. Chacko received a M.Sc. in economic and social history from Oxford University, where he was a Marshall Scholar, and a B.A. in biology, B.S. in gerontology, and minor in health policy and management from the University of Southern California as University Valedictorian. Profile
TWST: Can you describe Ignyta today and its business model?

Dr. Chacko: Ignyta is a San Diego-based biotech company focused on precision medicine in oncology. Some